MediWound (NASDAQ:MDWD) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS

MediWound (NASDAQ:MDWD) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23, RTT News reports. The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter last year, the business posted ($0.19) earnings per share.

MediWound Stock Performance

Shares of MediWound stock opened at $17.05 on Friday. MediWound has a one year low of $12.78 and a one year high of $24.00. The stock has a market cap of $183.90 million, a price-to-earnings ratio of -5.88 and a beta of 0.82. The stock has a 50 day moving average price of $18.18 and a 200-day moving average price of $17.60.

Analyst Upgrades and Downgrades

MDWD has been the subject of several research analyst reports. Craig Hallum initiated coverage on MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 price target for the company. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of MediWound in a report on Thursday.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.